Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mylan Inc.
BioCentury | Jan 10, 2025
Data Byte
FDA’s new and supplemental approvals in December
Agency approves at least nine new therapies; adds new indications or patient populations to a dozen marketed drugs
BioCentury | Mar 7, 2023
Data Byte
Biosimilar pegfilgrastims saved Medicare $500M in 2021
Part B pegfilgrastim spending fell from $1.4B in 2017 to $866M in 2021, with usage largely unchanged
BioCentury | Mar 11, 2022
Management Tracks
Sandrock joins board at Atalanta
Plus Imbria staffs C-suite and updates from Berkeley Lights, Akouos and more
BioCentury | Feb 5, 2022
Politics, Policy & Law
Congress starts loading the user-fee train
User-fee reauthorization is a locomotive that will pull a lot freight from Capitol Hill to the White House
BioCentury | Feb 4, 2022
Regulation
Generic Restasis, subject of failed sovereign immunity bid, approved
AbbVie had tried to shield its patent on the two-decade old drug by transferring it to a Native American tribe
BioCentury | Feb 3, 2022
Product Development
Feb. 2 Quick Takes: Pharming plans global submissions for leniolisib
Plus Novo ends Staten deal, new Pfizer vaccine data coming, Novartis scuttles pan-JAK and more
BioCentury | Oct 9, 2021
Market Access
Neulasta biosimilars have produced patchy savings for patients
Declining average sales prices for Neulasta and its biosimilars have lowered expenses for Medicare patients, but not necessarily for others
BioCentury | Jul 29, 2021
Product Development
July 28 Quick Takes: FDA approves first interchangeable biosimilar insulin for diabetes
Plus: Mega-rounds for Deep Genomics, Ring and more
BioCentury | Nov 7, 2019
Politics & Policy
Gilead to seek pause in U.S. government HIV PrEP suit until patent office rules on patent validity
BioCentury | Jun 15, 2019
Company News
June 13 Company Quick Takes: ISS rebuffs Takeda’s Weber; plus Sage, Blueprint, Tetraphase, Celgene and more
Items per page:
1 - 10 of 271